Clinical trials: PD-1 Inhibitors
Endometrial Cancer
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
This is a phase 2 study of investigational drug niraparib and TSR-042 in patients with advanced/recurrent endometrial cancer. The purpose of this study is to determine whether blocking a protein called poly (ADP-ribose)…
- Trial name
- NCT03016338
- Testing
- Niraparib, TSR-042
- Where
- 7 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Advanced Colorectal Cancer
Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer
This is a single-center, open-label, single-arm, exploratory phase II clinical trial designed to evaluate the preliminary efficacy and safety of sintilimab in combination with oral gossypol acetate in patients with advanced…
- Trial name
- NCT07656766
- Testing
- Sintilimab, Gossypol Acetate
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University People's Hospital
Hypopharyngeal Carcinoma
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
This is a multi-center, randomized controlled, prospective clinical study.
- Trial name
- NCT07248956
- Testing
- Finolizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Cisplatin
- Where
- 7 sites in China
- Volunteers
- 116 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Pancreatic Adenocarcinoma
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy for advanced disease.
- Trial name
- RiLEY (NCT06896188)
- Testing
- Retifanlimab, Chemotherapy, 9-ING-41
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Anwaar Saeed
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of Head and Neck
Pembrolizumab Plus Olaparib in LA-HNSCC
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck…
- Trial name
- NCT05366166
- Testing
- Pembrolizumab, Olaparib, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
NSCLC, Stage III, NSCLC, Stage IV
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies.
- Trial name
- NCT06512207
- Testing
- Leuprorelin acetate + Sintilimab, Sintilimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jinzhou Medical University
Esophageal Cancer
Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have longer overall survival.
- Trial name
- NCT07533357
- Volunteers
- 158 people
- Sponsor
- Fudan University
HCC
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence.
- Trial name
- NCT06311929
- Testing
- PD-1 monoclonal antibody and lenvatinib, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chen Xiaoping
Biliary Tract Cancer, Disitamab Vedotin
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
This trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with…
- Conditions
- Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
- Trial name
- NCT07159217
- Testing
- Disitamab Vedotin, Lenvatinib, Pembrolizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Liver Cancer
Probiotics Enhance the Treatment of PD-1 Inhibitors in Patients With Liver Cancer
Human microbes have been called "the second genome of humanity".On May 13,2016,the White House launched the National Microbiome Initiative (NMI), with an estimated investment of us $521 million, to elevate microbiome research to…
- Trial name
- NCT05032014
- Testing
- M9
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Hepatocellular Carcinoma
A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04411706
- Testing
- Sintilimab Combined With Apatinib and Capecitabine
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Xin-Hua Xu
Neoplasms, Colorectal, Solid Tumor
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Conditions
- Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
- Trial name
- SYLVER (NCT06710847)
- Testing
- GSK4418959, PD-1 inhibitor
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy
The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to anti-PD-1 immunotherapy in metastatic melanoma after 2…
- Trial name
- TEP-ANTI-PD1 (NCT03888950)
- Testing
- FDG PET-CT
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT03048500
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
The objective of our study is to assess the risk of immune-related adverse events associated with PD-1 inhibitors use compared to standard chemotherapy use in patients with non small cell lung cancer, using nationwide healthcare…
- Trial name
- NCT04115410
- Testing
- PD-1 inhibitor, Chemotherapy Drugs, Cancer
- Volunteers
- 4,724 people
- Sponsor
- Sungkyunkwan University
Immune-Related Adverse Events, Lupus Erythematosus, Systemic
Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
This study aims to identify a way to predict the side effects that some people with cancer experience when receiving immunotherapy.
- Conditions
- Immune-Related Adverse Events, Lupus Erythematosus, Systemic, Sjogren Syndrome, Systemic Sclerosis (SSc)
- Trial name
- INTER-AUTENTIC (NCT07249060)
- Testing
- Immune Checkpoint Inhibitors
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitario Araba
Hodgkin Lymphoma, Adult, Relapse
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles.
- Conditions
- Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma
- Trial name
- NCT05137886
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Refractory Malignant Ascites
Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites
The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.
- Trial name
- NCT05303844
- Testing
- H101, Tislelizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Advanced Solid Tumors
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the Recommended Phase 2 Dose (RP2D) of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in…
- Trial name
- NCT02179918
- Testing
- PF-05082566, MK-3475
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer